Other News

AMGEN PRESENTS NEW REPATHA® (EVOLOCUMAB) DATA AT AHA 2022

Very low LDL-C Levels <20 mg/dL Were Well Tolerated With no new Safety Signals and Were Associated With a Reduced Risk of Cardiovascular Outcomes Data Reinforces Long-Term Efficacy and Consistent Safety Profile of Repatha Observed in FOURIER-OLE THOUSAND OAKS, Calif., Nov. 7, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented a new analysis […]

Implicity to Participate in Health Tech Challengers Super Finals at HLTH 2022

Company named a Top 8 Super Finalist in the global health tech competition identifying the most disruptive companies shaping the future of digital health. CAMBRIDGE, Mass., Nov. 8, 2022 /PRNewswire/ — Implicity®, a leader in remote patient monitoring and cardiac data management solutions, announced it has been selected to participate in the Health […]

Successful First-in-Human Clinical Study of Kardium’s Next Generation Globe® Pulsed Field System

VANCOUVER, British Columbia–(BUSINESS WIRE)–Kardium Inc. announces the successful first-in-human study of its next generation Globe® Pulsed Field System to treat atrial fibrillation (AF) using pulsed field ablation (PFA) therapy. Working with Dr. Vivek Reddy1 from Mount Sinai Hospital (New York, USA), and Prof. Petr Neužil and Dr. Jan Petrů from Na Homolce […]

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension

Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action RARITAN, N.J., Nov. 7, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), […]

SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials

DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ — Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented today as Late-Breaking Clinical Science at the American Heart Association (AHA) Scientific Sessions 2022. With this news, Medtronic […]

Fujifilm Introduces SCENARIA View Focus Edition CT Scanner with Cardio StillShot, a new Cardiac Motion Correction Feature

Cardio StillShot enables 6x higher temporal resolution compared to conventional image reconstruction methods by detecting and correcting motion in the heart Lexington, MA, Nov. 08, 2022 (GLOBE NEWSWIRE) — FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced the U.S. launch of the SCENARIA View Focus Edition Computed Tomography […]

Shockwave Medical Reports Third Quarter 2022 Financial Results

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022. Recent Highlights Recognized revenue of $131.3 million […]

Keros Therapeutics Presents Preclinical Data from its KER-012 Program at the American Heart Association 2022 Scientific Sessions

LEXINGTON, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced results from a preclinical study of […]

InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update

– Generated 38.8% growth in CGuard™ revenue year-over-year –            – Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 –            – Announced strategic partnership with NAMSA, a med tech contract research organization (CRO), to accelerate […]

Neovasc Reducer Obtains U.S. Outpatient Reimbursement

VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for […]